ImmunoGen, Inc. (NASDAQ:IMGN) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 – RESULTS OF OPERATION AND FINANCIAL CONDITION
On August 2, 2019, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the company’s financial results for the quarter ended June 30, 2019. The press release announcing financial results for the quarter ended June 30, 2019 is included as Exhibit 99.1 and incorporated herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d): The following exhibit is being furnished herewith:
IMMUNOGEN INC Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 imgn_Current_folio_8K_Ex_99_1 Exhibit 99.1 ImmunoGen Reports Recent Progress and Second Quarter 2019Financial Results Registration Study for Mirvetuximab Soravtansine in Ovarian Cancer on Track to Start by Year-End Full Data from the Phase 3 FORWARD I Trial and Initial FORWARD II Triplet Data to be Presented at ESMO Recommended Phase 2 Dose and Schedule for IMGN632 Determined; Combination and MRD+ Protocol Filed Updated 2019 Financial Guidance Provided Conference Call to be Held at 8:00 a.m. ET Today Waltham,…
To view the full exhibit click here
About ImmunoGen, Inc. (NASDAQ:IMGN)
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.
